PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
I have a PhD in political science and have been investing for well over a decade. I generally follow small cap biotechnology, MLPs, and mining companies. I hope to provide my thoughts on both topics of interest to investors and particular companies.
See all of my reports at www.sobekanalytics.com
Follow me on twitter: @dsobek.
Private Investor with 10 years of biotech trading experience.
I use basic disciplined research approach to discover new investment ideas. Biotech sector is full of violent stock moves and trial failures. On one hand it requires traders to be quick on their feet and on the other hand it forces investors to have a great deal of patience.
I enjoy the challenge of mining for hidden gems, because its 10 times as hard to do that than predicting failures. Failure is the norm in biotech, I look for exception to the norm!
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes online trading since 1997, working as a pharmacist during 2004-2014, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
I have been trading max pain type data since 2007 after noting odd trading patterns centered around options expiry. I am a more conservative trader/investor and only take high probability trades. I prefer to know where stocks won’t be rather than guess where they will be. Trading with this mind set gives you 80% plus probability of being correct.
I have always been a stock market enthusiast. My formal training is that of informal. I am self taught, soaking up as much knowledge as can be absorbed. I love the financial industry and would work for free. I am a fundamental investor at heart and like crunching the numbers. I picked up on Max Pain theory and use option data as a main thesis in taking my positions.
In the beginning; when studying Max Pain I was truly amazed at the power it had in pulling or pushing AAPL around. I have seen the stock drop 5% out of nowhere with no news. The only news would be it was the 3rd Friday of the month. I then picked up on hitting the Max Pain strike was about 50/50 odds. Max Pain would give you a tell on what direction AAPL would start heading for expiry. I started to build a strategy from my studies. Using the Max Pain strike is not really tradable, good to know, but not tradable. So I started to study open interest (OI) and its affect on AAPL. Long story short, I have altered the original Max Pain theory and morphed it into what my own studies have concluded. I call this OI/Max Pain, it uses open interest and a range. This way it is tradable as I now have a high probability range. It doesn’t stop there, using OI will tell you so much more. How a stock reacts at each strike depending on the amount of OI is a major tell.
Conclusion: When using open interest you can accomplish multiple things. We can use it for OI/Max Pain when AAPL is stuck in a range and we can use it for catching breakouts, breakdowns, buy and sell points. Enjoy.
I want to give a special thanks to some of my early influences: Turley Muller, Andy Zaky and Jason Schwarz. I thank Philip Elmer-Dewitt for his coverage on AAPL and letting us have a voice, Horace Dediu for his tireless studies and anyone attached to the AAPL community.
StockMatusow.com Writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Scott has his own online talk show which can be heard at www.scottmatusow.com/radio .
During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about.
Other places you can follow Scott are:
Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com.
Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector.
Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations.
As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points.
Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis
Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com
Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.
Michael can be followed at www.twitter.com/MMK_3399 @MMK_3399
I am an individual investor who has been operating strictly in the biotech sector over the last five years. I currently do not engage in any options trading but expect that will change as I become more experienced and comfortable with the concepts and strategies.
I am frequently on Twitter: @kevinccc
I’m a baby boomer, who over the years has been fortunate enough to build some wealth, learn to invest and trade, and yet has not forgotten my basic blue collar, mid-western values. Via Common Cents, I strive to provide a basic, down to earth, main street view of the equity markets, general trends, and specific investment ideas without the Wall Street noise, spin, and complexity. It is my hope that my insights can contribute in a small way to the improved socialization of investment advice for the benefit of all individual investors.
From a background perspective, I have a computer science degree from the University of Illinois, have held senior executive management positions in major IT and management consulting firms, live in the Chicago area with my wife, and enjoy golfing and cheering for Chicago sports teams.
Kim Klaiman is a full time options trader and founder of SteadyOptions.com. He trades mostly non-directional strategies, like pre-earnings strangles and iron condors. Likes to trade strategies with negative correlation. He lives in Toronto, Canada.
Visit the SteadyOptions.com forum. SteadyOptions offers a combination of a high quality education and actionable trade ideas using variety of Non-Directional option trading strategies for Steady and Consistent Profits.
Follow me on Twitter: https://twitter.com/SteadyOptions_
SteadyOptions performance: https://steadyoptions.com/performance
After 25 years as an executive in the financial services industry -- and a dozen more years split between the high-tech industry and the public sector -- I left to pursue endeavors that were more fulfilling on a personal level and more contributory on a societal level.
When people ask what I do, I often say that "I dabble." That's only half facetious. I have a lot of interests and feel liberated by no longer being tied to a corporate title (though technically I am President of an investment advisory firm, I-Pension LLC, in which I am a co-owner).
I've always been -- and have always wanted to be -- a writer. I've written dozens of articles for magazines on topics ranging from the physiology of sweat to Lincoln's attempt to hire Garibaldi to head up the Union army. My book topics are equally varied:
-- "Walden 3.0: A Dystopian Romance" (Erewhon Press, 2011): a novel introducing a utopian community with a range of cultural attributes and belief systems that will alternately delight and dismay pretty much everyone.
-- "Your Nest Egg Game Plan" (Career Press, 2009): a how-to guide, co-authored with Prof. Craig Israelsen of BYU, designed to help middle-income investors make the most of their savings by focusing on diversification and low expenses.
-- "Marketing for Rainmakers: 52 Rules of Engagment to Attract and Retain Customers for Life" (Wiley, 2009): a collection of business-building and loyalty-inspiring marketing ideas to help build a business and a personal brand.
In addition to writing, I'm an adjunct professor at Boston College where I teach at both the graduate and undergraduate level. I've found this interactive dialogue with young minds to be the most enjoyable and rewarding work of my career.
If there's one common element to my diverse experience it's a focus on translating complicated subject matter into language that is simple and understandable. I like to put myself in the place of the client, student, or reader and craft messages that resonate and motivate.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
I am an independent trader and investor seeking opportunities in energy, deep value, distressed and turnaround plays. I also invest in growth when I see a sustainable long term trend in certain stocks or sectors.
I may occasionally send stock ideas out on Twitter, if exceptional opportunities arise: @rougetrades
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy